Bedaquiline
| Title | Journal |
|---|---|
| Supramolecular strategy for reducing the cardiotoxicity of bedaquiline without compromising its antimycobacterial efficacy. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20180901 |
| Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. | Antimicrobial agents and chemotherapy 20140101 |
| Rational drug design based synthesis of novel arylquinolines as anti-tuberculosis agents. | Bioorganic & medicinal chemistry letters 20131115 |
| Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains. | Journal of medicinal chemistry 20130523 |
| 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. | Lancet (London, England) 20120915 |
| Tuberculosis: the drug development pipeline at a glance. | European journal of medicinal chemistry 20120501 |
| Discovery of selective menaquinone biosynthesis inhibitors against Mycobacterium tuberculosis. | Journal of medicinal chemistry 20120426 |
| Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. | Journal of acquired immune deficiency syndromes (1999) 20120415 |
| Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. | PloS one 20120101 |
| Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. | American journal of respiratory and critical care medicine 20110915 |
| The TB Alliance: overcoming challenges to chart the future course of TB drug development. | Future medicinal chemistry 20110801 |
| Synthesis and antimycobacterial activity of prodrugs of indeno[2,1-c]quinoline derivatives. | European journal of medicinal chemistry 20110401 |
| Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. | PloS one 20110101 |
| Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. | PloS one 20110101 |
| [Present and future in the use of anti-tubercular drugs]. | Pneumologia (Bucharest, Romania) 20110101 |
| Drugs in development for tuberculosis. | Drugs 20101203 |
| Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20101201 |
| Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. | Tuberculosis (Edinburgh, Scotland) 20100901 |
| [R207910 (TMC207): a new antibiotic for the treatment of tuberculosis]. | Medecine et maladies infectieuses 20100701 |
| In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. | Antimicrobial agents and chemotherapy 20100701 |
| Current development and future prospects in chemotherapy of tuberculosis. | Respirology (Carlton, Vic.) 20100701 |
| TMC207: the first compound of a new class of potent anti-tuberculosis drugs. | Future microbiology 20100601 |
| Update in tuberculosis 2009. | American journal of respiratory and critical care medicine 20100315 |
| Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. | American journal of respiratory and critical care medicine 20090915 |
| Design, synthesis, biological evaluation and molecular modelling studies of novel quinoline derivatives against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry 20090401 |
| A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. | American journal of respiratory and critical care medicine 20090101 |
| Once-weekly treatment of tuberculosis with the diarylquinoline R207910: a real possibility. | American journal of respiratory and critical care medicine 20090101 |
| [Some new antitubercular agents]. | Revue medicale suisse 20080319 |
| New anti-tuberculosis drugs with novel mechanisms of action. | Current medicinal chemistry 20080101 |
| In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. | Antimicrobial agents and chemotherapy 20071101 |
| New tuberculosis therapeutics: a growing pipeline. | The Journal of infectious diseases 20070815 |
| A computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new drug candidate R207910. | Proteins 20070601 |
| New drugs being developed for the treatment of tuberculosis. | Expert opinion on investigational drugs 20050701 |
| New small-molecule synthetic antimycobacterials. | Antimicrobial agents and chemotherapy 20050601 |
| A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. | Science (New York, N.Y.) 20050114 |
| Microbiology. TB--a new target, a new drug. | Science (New York, N.Y.) 20050114 |
| Medicine. New TB drug promises shorter, simpler treatment. | Science (New York, N.Y.) 20041210 |